Article Details

Pfizer-Backed DEM Bio Launches to Leverage CRISPR in Immuno-Oncology - PharmaLive

Retrieved on: 2022-06-23 14:14:22

Tags for this article:

Click the tags to see associated articles and topics

Pfizer-Backed DEM Bio Launches to Leverage CRISPR in Immuno-Oncology - PharmaLive. View article details on hiswai:

Excerpt

DEM BioPharma, backed by an impressive list of investors, debuted Thursday with $70 million that will assist in its efforts to treat cancer with ...

Article found on: www.pharmalive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up